The CRISPR FORUM 2017: CRISPR - Drug discovery tool or therapeutic revolution?

CO-CHAIRS: Professor Eric Hendrickson (University of Minnesota Medical School) and Dr Jon Moore (Horizon Discovery)


The discovery of the RNA programmable nucleases Cas9 and Cpf1 has revolutionized a researcher's ability to interrogate and understand genes. The impact of CRISPR genome editing technology has been universal and unescapable, bringing drug discovery to an era of whole genome knockout screens and development of translational in vitro and in vivo models of disease, as well as moving into the clinic, progressing towards transformative gene-based therapies for human diseases.

This unique meeting was held in Dublin on 17-18 October and brought together leaders in the field together with a wide academic and commercial audience, to explore the new horizons in drug development and therapeutics brought by advancements in CRISPR technology.

What made this meeting different:

  • A substantial proportion of the oral program was given to talks selected from submitted abstracts to discuss innovative ideas
  • There was a focus on closing the gap between new developments in CRISPR technology and application in life sciences
  • There were networking opportunities at the attendee dinner at a famous venue in Dublin

This event was held in association with The Pathologist, media partner to The CRISPR Forum 2017.

The CRISPR Forum 2017 was also sponsored by GEN - Genetic Engineering and Biotechnology News.

Join The CRISPR Journal Community and find out about this new publication, launching 2018.


Tuesday 17 October


CRISPR-Cas9 as a new chapter in the history of gene editing (13:00-13:45)

13:00 - Eric Hendrickson (Minnesota) - Mechanism of gene editing

Therapeutic applications of CRISPR-Cas9 (13:45-14:50)

13:45 - Linda Popplewell (RHU) - Towards therapy of Duchenne Muscular Dystrophy

14:10 - Patrick Harrison (Cork) - Homology Independent Targeted Integration to correct multiple Cystic Fibrosis mutations

14:35 - Speaker TBC

Break (14:50-15:20)

Improvements in CRISPR Technology (15:20-17:10)

15:20 - Anna Cersesoto (University of Trento) - From user to genome-friendly CRISPR-Cas9

15:45 - Marcello Maresca (AstraZeneca) - In vivo base editing and genome editing for target validation and disease modelling

16:00 - Thomas Machleidt (Promega) - CRISPR-mediated tagging of endogenous proteins with a luminescent peptide

16:15 - Nadia Hegarat (University of Sussex) - Development of new chemical genetics approaches in human cell lines based on CRISPR mediated gene

16:40 - TBA (Labcyte)

17:00 - Ben Kleinstiver (Massachusetts General Hospital) - Improving the specificity and versatility of CRISPR nucleases

Attendee dinner in evening


Wednesday 18 October


Target ID and validation A (09:00-10:40)

09:00 - Carlos le Sage (Horizon) - Compare and contrast CRISPR KO, CRISPRi and CRISPRa

09:25 - Jon Moore (Horizon) - Synthetic lethal target ID

09:50 - Melissa Kelley (Dharmacon) - TBC

10:15 - Paul Datlinger (Austrian Academy of Sciences) - CROP-seq: pooled CRISPR screens with single cell transcriptome readout

Break (10:40-11:10)

Target ID and validation B (11:10-12:45)

11:10 - Shanade Dunn (Sanger Inst) - CRISPR-Cas9 screening to identify novel combination targets for PI3K pathway inhibitors in breast cancer

11:25 - Yaron Galanty (University of Cambridge) - TBA, Whole genome CRISPR screens

11:50 - Colm Ryan (University College Dublin) - Cancer GD: a bioinformatics tool

12:05 - Tilmann Buerkstuemmer (Horizon) - Using CRISPR for rapid generation of conditional mutants

12:30 - Jonathan Wrigley (AstraZeneca) - Precise genome editing: generating CRISPR models of disease and drug resistance

Lunch and Networking

Applications (14:15 – 16:20)

14:15 - Andrew Bassett (Sanger Inst) - Using CRISPR to understand miRNA target site regulation

14:40 - Kilian Huber (SGC, Oxford) - Target ID via proteomics and CRISPR/Cas9

15:05 - Zhi Liu (System Biology Ireland, UCD) - Functional analysis of the MAPK scaffold KSR1 in malignant melanoma

15:20 - Srinivas Suda (Natn. Inst. Cell. Biotech, Dublin) - Engineering miRNA to enhance CHO cell performance in biopharma productivity

15:35 - Sarah Stewart (University of Cambridge) - A genome-wide CRISPR screen reconciles the role of N-linked glycosylation in galectin-3 transport to the cell surface

15:50 - Michael D’Angelo (University of Cambridge) - CRISPR/Cas9 genome edited models of STAT3 activated lysosome mediated cell death in mammary epithelial cells.

Closing remarks (16:05-16:20)

16:05 - Jon Moore - Closing remarks



Areas of particular interest included:

  • Technical advancements
  • CRISPR Drug Discovery and development
  • Cell Therapy




If you are involved in arranging similar educational meetings and conferences, and looking for support, please do let us know by emailing


Find out more about Horizon CRISPR Screening



October 17 - 18, 2017

Starting 12:00 AM - 12:00 AM

event title
Share this page